Displaying publications 141 - 160 of 55592 in total

Abstract:
Sort:
  1. Schweiker M, Abdul-Zahra A, André M, Al-Atrash F, Al-Khatri H, Alprianti RR, et al.
    Sci Data, 2020 01 06;7(1):11.
    PMID: 31907360 DOI: 10.1038/s41597-019-0348-3
    An amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Matched MeSH terms: Humans
  2. PLOS ONE Staff
    PLoS One, 2020 01 29;15(1):e0228662.
    PMID: 31995618 DOI: 10.1371/journal.pone.0228662
    [This corrects the article DOI: 10.1371/journal.pone.0220411.].
    Matched MeSH terms: Humans
  3. Yeo JG, Wasser M, Kumar P, Pan L, Poh SL, Ally F, et al.
    Nat Biotechnol, 2020 06;38(6):757.
    PMID: 32467644 DOI: 10.1038/s41587-020-0574-4
    An amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Matched MeSH terms: Humans
  4. Alina MF, Azma RZ, Norunaluwar J, Azlin I, Darnina AJ, Cheah FC, et al.
    J Hum Genet, 2020 07;65(7):635.
    PMID: 32385338 DOI: 10.1038/s10038-020-0766-2
    An amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Matched MeSH terms: Humans
  5. Mathew M, Makhankova A, Menier D, Sautter B, Betzler C, Pierson B
    Sci Rep, 2020 Jun 04;10(1):9348.
    PMID: 32493945 DOI: 10.1038/s41598-020-66550-4
    An amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Matched MeSH terms: Humans
  6. Chang CY
    QJM, 2021 02 18;114(1):55.
    PMID: 32330273 DOI: 10.1093/qjmed/hcaa140
    Matched MeSH terms: Humans
  7. Binns C, Yun Low W
    Asia Pac J Public Health, 2022 Nov;34(8):749-751.
    PMID: 36398870 DOI: 10.1177/10105395221132915
    Matched MeSH terms: Humans
  8. Kow CS, Ramachandram DS, Hasan SS
    Arch Med Res, 2022 09;53(6):643.
    PMID: 36030115 DOI: 10.1016/j.arcmed.2022.08.004
    Matched MeSH terms: Humans
  9. Noh MSF, Bahari N, Abdul Rashid AM
    J Neuroradiol, 2021 Nov;48(6):453-455.
    PMID: 31837378 DOI: 10.1016/j.neurad.2019.12.002
    Matched MeSH terms: Humans
  10. Cheo SW, Abdul Rashid WNFA, Ho CV, Ahmad Akhbar RZ, Low QJ, Rajahram GS
    Hong Kong Med J, 2021 08;27(4):287-289.
    PMID: 34413256 DOI: 10.12809/hkmj208815
    Matched MeSH terms: Humans
  11. Islam MK, Stanslas J
    Pharmacol Ther, 2021 11;227:107870.
    PMID: 33895183 DOI: 10.1016/j.pharmthera.2021.107870
    Cancer immunotherapy is an option to enhance physiological defence mechanism to fight cancer, where natural substances (e.g., antigen/antibody) or small synthetic molecule can be utilized to improve and restore the immune system to stop or slacken the development of malignant cells, stop metastasis and/or help the immune response with synthetic monoclonal antibodies (mAbs) and tumour-agnostic therapy to eliminate cancer cells. Interaction between the programmed cell death ligand 1 (PD-L1) and its receptor (programmed cell death protein 1, PD-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) linked signalling pathways have been identified as perilous towards the body's immune mechanism in regulating the progression of cancer. It is known that certain cancers use these pathways to evade the body's defence mechanism. The immune system is capable of responding to cancer by stalling these trails with specific synthetic antibodies or immune checkpoint inhibitors, which can ultimately either stop or slow cancer cell development. Recent findings and data suggested that using such inhibitors invigorated a new approach to cancer treatment. These inhibitors usually activate the immune system to identify and eliminate cancer cells rather than attacking tumour cells directly. PD-1/PD-L1 inhibitors have already been substantiated for their efficacy in over twenty variations of cancer through different clinical trials. Studies on molecular interaction with existing PD-1/PD-L1 inhibitors that are mainly dominated by antibodies are constantly generating new ideas to develop novel inhibitors. This review has summarised information on reported and/or patented small molecules and peptides for their ability to interact with the PD-1/PD-L1 as a potential anticancer strategy.
    Matched MeSH terms: Humans
  12. Sorokowski P, Randall AK, Groyecka A, Frackowiak T, Cantarero K, Hilpert P, et al.
    Front Psychol, 2017;8:1728.
    PMID: 29021774 DOI: 10.3389/fpsyg.2017.01728
    [This corrects the article on p. 1199 in vol. 8, PMID: 28785230.].
    Matched MeSH terms: Humans
  13. Sartelli M, Weber DG, Ruppé E, Bassetti M, Wright BJ, Ansaloni L, et al.
    World J Emerg Surg, 2017;12:35.
    PMID: 28785301 DOI: 10.1186/s13017-017-0147-0
    [This corrects the article DOI: 10.1186/s13017-016-0089-y.].
    Matched MeSH terms: Humans
  14. Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al.
    World J Emerg Surg, 2017;12:36.
    PMID: 28785302 DOI: 10.1186/s13017-017-0148-z
    [This corrects the article DOI: 10.1186/s13017-017-0141-6.].
    Matched MeSH terms: Humans
  15. Heidari MH, Movafagh A, Abdollahifar MA, Abdi S, Barez MM, Azimi H, et al.
    Anat Cell Biol, 2017 Jun;50(2):162.
    PMID: 28713622 DOI: 10.5115/acb.2017.50.2.162
    [This corrects the article on p. 69 in vol. 50, PMID: 28417057.].
    Matched MeSH terms: Humans
  16. Lam HY, Yeap SK, Pirozyan MR, Omar AR, Yusoff K, Abd-Aziz S, et al.
    Biomed Res Int, 2017;2017:4529437.
    PMID: 29333441 DOI: 10.1155/2017/4529437
    [This corrects the article DOI: 10.1155/2011/718710.].
    Matched MeSH terms: Humans
  17. Wang X, Yu G, Wang J, Zain AM, Guo W
    Bioinformatics, 2022 Nov 15;38(22):5092-5099.
    PMID: 36130063 DOI: 10.1093/bioinformatics/btac643
    MOTIVATION: Cancer subtype diagnosis is crucial for its precise treatment and different subtypes need different therapies. Although the diagnosis can be greatly improved by fusing multiomics data, most fusion solutions depend on paired omics data, which are actually weakly paired, with different omics views missing for different samples. Incomplete multiview learning-based solutions can alleviate this issue but are still far from satisfactory because they: (i) mainly focus on shared information while ignore the important individuality of multiomics data and (ii) cannot pick out interpretable features for precise diagnosis.

    RESULTS: We introduce an interpretable and flexible solution (LungDWM) for Lung cancer subtype Diagnosis using Weakly paired Multiomics data. LungDWM first builds an attention-based encoder for each omics to pick out important diagnostic features and extract shared and complementary information across omics. Next, it proposes an individual loss to jointly extract the specific information of each omics and performs generative adversarial learning to impute missing omics of samples using extracted features. After that, it fuses the extracted and imputed features to diagnose cancer subtypes. Experiments on benchmark datasets show that LungDWM achieves a better performance than recent competitive methods, and has a high authenticity and good interpretability.

    AVAILABILITY AND IMPLEMENTATION: The code is available at http://www.sdu-idea.cn/codes.php?name=LungDWM.

    SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

    Matched MeSH terms: Humans
  18. Raja Shariff RE, Ting Yuen B, Mohd Ghazi A
    Eur Heart J Acute Cardiovasc Care, 2022 Nov 02;11(10):e1-e2.
    PMID: 36322822 DOI: 10.1093/ehjacc/zuac058
    Matched MeSH terms: Humans
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links